Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Bank of America Corp DE

Bank of America Corp DE lowered its stake in Perspective Therapeutics, Inc. (NYSE:CATX) by 72.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,777 shares of the company’s stock after selling 125,567 shares during the quarter. Bank of America Corp DE owned about 0.07% of Perspective Therapeutics worth $156,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of CATX. Affinity Asset Advisors LLC lifted its holdings in Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock worth $4,147,000 after purchasing an additional 800,000 shares during the period. Walleye Capital LLC lifted its holdings in Perspective Therapeutics by 2,526.2% in the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company’s stock valued at $1,518,000 after acquiring an additional 457,675 shares during the last quarter. Jump Financial LLC acquired a new stake in Perspective Therapeutics in the 4th quarter valued at about $688,000. JPMorgan Chase & Co. lifted its holdings in Perspective Therapeutics by 498.3% in the 4th quarter. JPMorgan Chase & Co. now owns 149,045 shares of the company’s stock valued at $475,000 after acquiring an additional 124,133 shares during the last quarter. Finally, Aristides Capital LLC acquired a new stake in Perspective Therapeutics in the 4th quarter valued at about $187,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $3.61 on Tuesday. The company’s fifty day moving average is $2.51 and its 200-day moving average is $2.84. Perspective Therapeutics, Inc. has a 12 month low of $1.60 and a 12 month high of $16.55.

Insider Transactions at Perspective Therapeutics

In other news, Director Robert F. Williamson III bought 22,192 shares of the stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the purchase, the director now owns 70,837 shares of the company’s stock, valued at $160,799.99. This represents a 45.62% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Johan M. Spoor bought 22,026 shares of the stock in a transaction that occurred on Friday, March 28th. The stock was purchased at an average price of $2.24 per share, for a total transaction of $49,338.24. Following the completion of the purchase, the chief executive officer now directly owns 59,383 shares in the company, valued at $133,017.92. The trade was a 58.96% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 115,696 shares of company stock worth $256,344 in the last 90 days. 3.72% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CATX shares. Royal Bank of Canada raised shares of Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and upped their price target for the company from $15.00 to $16.00 in a report on Tuesday, June 3rd. Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Truist Financial cut their price target on shares of Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research report on Monday, March 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $12.63.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.